Pharmaceutical stocks with a market capitalization of 19 enterprises, this field of "black horse" frequently.

"Pharmaceutical Network Industry Dynamics" Since this year, pharmaceutical stocks continue to rise, Hengrui Pharmaceuticals, Pharmaceutical Mingkang, Changchun High-tech, Huahai Pharmaceuticals and many other pharmaceutical stocks have repeatedly reached new highs at the same time, there were a few hundred billion market value clubs, but also ushered in a large-scale expansion of the army.A-shares and Hong Kong stocks, with a total of eight new pharmaceutical companies adding more than $100 billion in mid-July.if the market once touched the hundreds of billions of points, the number of up to 10.the pharmaceutical stocks of 100 billion market capitalization of 19 enterprises, this area "black horse" frequency, as of July 17, a total of 10 A-shares with a market value of 10 billion pharmaceutical stocks, five new companies into the market., Hengrui Pharmaceuticals broke through the 500 billion mark, sitting firm lying in the chair, the total market value of up to 511.305 billion yuan.followed by Murray Medical with a market capitalisation of $402.029 billion.in general, these enterprises cover innovative drugs, medical devices, medical services, Chinese medicine, vaccines and other sub-sectors, including more vaccine enterprises.and the Hong Kong stock market pharmaceutical stocks feast, earlier than the A-shares.at the end of last year, Hong Kong stocks of six companies with a market capitalisation of 100 billion companies, all from the biopharmaceutical sector, mainland enterprises covering the pharmaceutical mingkang, Hansen Pharmaceuticals, Pharmaceutical Sinbet Bio, China Biopharmaceuticals, Stone Pharmaceutical Group.and so on this year, Hong Kong stocks of hundreds of billions of pharmaceutical stocks newly promoted three, including Ali Health, Ping An good doctor and other two flow stars.a pharmaceutical carnival sweeping A-shares and Hong Kong stocks is on going on.it is worth noting that the pharmaceutical industry is a complex segment of the field, the list of hundreds of billions of market value of enterprises, can be subdivided into biopharmaceuticals, medical equipment services, Chinese medicine and other three major topics.and from the above-mentioned enterprises, biopharmaceutical, is undoubtedly the main protagonist of this pharmaceutical stock carnival, especially vaccine research and development enterprises, because of technical barriers and the impact of the epidemic, is becoming a big winner in the market.in fact, with the domestic health insurance into the stock game era, the result is that pharmaceutical enterprises need to increase research and development efforts to the transformation of innovative pharmaceutical enterprises.so innovative drugs in the biological drug, vaccines and other fields began to attract more and more investors to compete for the layout., well-known investment institutions, GaoGao Capital is now set to increase the list of battles, and pharmaceutical and biological stocks are its preferred areas.and from the public fund, the second quarter of the public fund on the pharmaceutical biological stocks holding is still large, the entire pharmaceutical biological industry, there are 133 stocks by the fund heavy holding, in addition to the public fund has been "holding" Hengrui Pharmaceutical, Changchun High-tech, Meirui Medical, pharmaceutical Mingkang, Zhifei biology, Eyre, Taige Ophthalmology, Kantai Biology and other stocks are held in the second quarter., according to the data, the biopharmaceutical sector rose about 28% in the first two quarters of this year, only calculated the second quarter of the increase of 21%, far outperforming the broader market.looking ahead to investment opportunities in the pharmaceutical sector in the third quarter, industry experts believe that further screening can be made based on the disclosure in the second quarter.in general, the pharmaceutical and biological industry has two attributes of science and technology and people's livelihood needs, driven by scientific and technological innovation, population aging, consumption upgrading, the future development of China's pharmaceutical industry is still promising, in addition to the field of biomedicine, other sub-sectors are also worth intervening and long-term adherence..